Log in
Create new account
home
boards
job center
archives
company monitor
cp wire
device news
pharmagather
advertise
contact us
Home
Avonex
2013 Should Be Interesting for Multiple Sclerosis Drugs
2013 Should Be Interesting for Multiple Sclerosis Drugs
Motley Fool
Aubagio
Avonex
Bayer
Betaseron
BG-12
Biogen Idec
Copaxone
Elan
Extavia
Gilenya
Merck KGaA
MS
multiple sclerosis
Novartis
Pfizer
Rebif
Sanofi
Teva
Tysabri
Is Biogen Too Good To Be True?
Is Biogen Too Good To Be True?
Seeking Alpha
Avonex
BiogenIdec
Fampyra
Fumaderm
Tysabri
Biogen, Bayer MS Drugs Aren’t Cost Effective, Study Says
Biogen, Bayer MS Drugs Aren’t Cost Effective, Study Says
Bloomberg
Avonex
Bayer
Betaseron
Biogen Idec
MS
multiple sclerosis
Biogen’s 'Avonex Pen' wins tentative EU nod
Biogen’s 'Avonex Pen' wins tentative EU nod
Bizjournals.com
Avonex
Avonex pen
Biogen Idec
Europe
MS
multiple sclerosis
News
Biotech Firms Fight Generics
WSJ Online
Amgen
anemia
arthritis
Avonex
Biogen Idec
biotech
Enbrel
Epogen
generics
MS
multiple sclerosis
Pfizer
News
Biogen Starts Patient Enrollment
Yahoo/Zacks.com
Abbott Laboratories
Acorda Therapeutics
Avonex
Biogen Idec
daclizumab
MS
»
8 comments
news tags
Abbott Laboratories
Amgen
Arena Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
biotech
Boston Scientific
Bristol-Myers Squibb
cancer
Celgene
China
Dendreon
diabetes
earnings
Eli Lilly
Europe
FDA
generics
Genzyme
GSK
hepatitis C
investors
JNJ
lawsuits
layoffs
M&A
Management
Medtronic
Merck
Novartis
obesity
patents
Pfizer
prostate cancer
Roche
Sanofi
Teva Pharmaceuticals
vaccines
Vivus
more tags
Yahoo! Finance
Quote for ABT